ANCA Associated Vasculitis, Giant Cell Arteritis, Idiopathic Inflammatory Myopathies, Inflammatory Rheumatism, Polymyalgia Rheumatica, Systemic Autoimmune Disease
Conditions
Brief summary
To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid therapy. In patients with inflammatory rheumatic disorders requiring prolonged glucocorticoid therapy, such tool could be useful to adapt first-line treatment decisions (in daily practice and in future clinical trials). The main objective of the study is to identify routine clinical, biological and DXA baseline characteristics predictive of the occurrence of clinically relevant complications of glucocorticoid therapy at 1 year, in order to propose a predictive score.
Interventions
None listed
Sponsors
University Hospital, Brest
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Life expectancy \> 1 year. * Indication to initiate prolonged glucocorticoid therapy at a dosage ≥ 15 mg/day for the treatment of an inflammatory rheumatic disease. * Initial treatment or relapse. * Previsional treatment duration \> 3 months.
Exclusion criteria
* Unable to consent. * Previous corticosteroid therapy in the last 3 months at a significant dosage (\> 5 mg per day).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinically relevant complication of glucocorticoid therapy | 1 year | The occurrence of one or more clinically relevant complication of glucocorticoid therapy during the first year of treatment, according to the Glucocorticoid Toxicity Index (items and specific list). |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life assessed through SF-36 | 1 year |
Countries
France
Outcome results
None listed